Company Overview of Broad Institute of MIT and Harvard
7 Cambridge Center
Cambridge, MA 02142
Key Executives for Broad Institute of MIT and Harvard
President and Founding Director
Associate Member and Director of Stanley Center for Psychiatric Research
Compensation as of Fiscal Year 2016.
Broad Institute of MIT and Harvard Key Developments
Monsanto Enters into Licensing Agreement with Broad Institute of MIT and Harvard for the Use of the CRISPR-Cas Genome-Editing Technology in Agriculture
Sep 23 16
Monsanto Company has entered into a global licensing agreement for the use of the CRISPR-Cas genome-editing technology in agriculture with the Broad Institute of MIT and Harvard. Under the agreement, the Broad Institute grants Monsanto a worldwide non-exclusive license for agriculture applications of the CRISPR-Cas technology.
AMRI Enters into Non-Exclusive Commercial License Agreement with Broad Institute of MIT and Harvard for the Use of CRISPR-Cas9 Gene Editing Technology
Aug 23 16
AMRI announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology and has completed several projects for its customers. The company will continue to use the technology to enhance its drug discovery service offerings and internal research and development. The CRISPR/Cas system serves as a naturally-occurring bacterial immune system that confers resistance to foreign genetic elements such as those from viruses. It has been developed as a precise method for editing the genetic code in mammalian cells, which allows researchers to effectively knock out or enhance the expression of targeted genes. It offers great utility in the development of in vivo and in vitro disease models, which are important for drug discovery research. Under the terms of the commercial use license, AMRI gained access to IP related to CRISPR-Cas9 technology that is being used to enhance AMRI's drug discovery services offerings and associated client programs. The application of CRISPR-Cas9 technology benefits a number of the specific services that AMRI provides to its customers, including protein production, cell line and assay development, high content screening and analysis, and target validation and assessment.
Evotec Enters Licence Agreement for Access to CRISPR-CAS9 Gene Editing Technology
Jul 6 16
Evotec AG announced that it has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology. Under the terms of this research tool licence, company gains access to IP related to CRISPR-Cas9 and will apply the technology to its drug discovery offerings and R&D activities, especially for the development of research tools and in target identification, and to further strengthen its post phenotypical screening target deconvolution platform. With this agreement, Evotec obtains non-exclusive access to the leading technology on the market for gene editing.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries